IDEXX Laboratories Inc. (IDXX) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (62% profit margin, 30% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
IDEXX Laboratories Inc. (IDXX) surged +2.32% to $575.98 as options desks priced 59% call premium vs. 41% put protection around the $564 max-pain magnet. High-quality cash engine (62% profit margin, 30% return on capital) with steady institutional support.
IDEXX Laboratories has delivered a 28.4% gain over the past three years, yet its recent share price swings and shifting expectations now put the spotlight squarely on one question. Are the cash flows that this veterinary
BTIG suspends Buy rating on IDEXX Laboratories (NASDAQ:IDXX).
COR's Q4 earnings are likely to benefit from strong specialty pharma demand and MSO growth, but pricing pressures and higher interest costs may weigh on results.
RVTY's Q3 earnings may gain from recovering pharma demand, stronger HCS demand and software growth, despite lingering spending and TB-related headwinds.
STE's second-quarter fiscal 2027 earnings may benefit from Healthcare growth, recent acquisitions, easing AST comparisons and continued margin expansion.
IDEXX Laboratories (NASDAQ:IDXX) is scheduled to report its earnings on Monday, November 2, 2026. The company has a market value of about $45.5 billion. Over the last twelve months it generated $4.6 billion in revenue an
Is ZTS a good stock to buy? We came across a bullish thesis on Zoetis Inc. on D Invests’s Substack. Since the thesis was published on June 26th, ZTS shares have edged higher as livestock and international sales partly of
BrightSpring gears up for Q3 earnings, with strong Specialty, Infusion and Provider Services growth expected to offset IRA headwinds. Can it beat estimates?
ZBH heads into Q3 earnings with growth expected in Hips, S.E.T. and Technology & Data, while Knee sales face ongoing pressure.
WAT's Q3 results are likely to benefit from strong revenue growth prospects, rising demand and acquisition gains.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +10.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IDXX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IDXX. Explore sector supply chains on /butterfly.
Why IDXX Stock surged +2.32% Today — RQD Quant Desk Flash. High-quality cash engine (62% profit margin, 30% return on capital) with steady institutional support.